Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Waycross Partners LLC

Waycross Partners LLC cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,349 shares of the medical equipment provider’s stock after selling 3,094 shares during the period. Intuitive Surgical accounts for approximately 3.3% of Waycross Partners LLC’s investment portfolio, making the stock its 8th largest holding. Waycross Partners LLC’s holdings in Intuitive Surgical were worth $17,660,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. OFI Invest Asset Management acquired a new position in Intuitive Surgical during the 3rd quarter valued at about $25,000. Baystate Wealth Management LLC boosted its position in shares of Intuitive Surgical by 150.0% during the fourth quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 45 shares during the period. MCF Advisors LLC grew its holdings in Intuitive Surgical by 108.1% in the 4th quarter. MCF Advisors LLC now owns 77 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 40 shares in the last quarter. Headinvest LLC acquired a new stake in Intuitive Surgical in the 3rd quarter valued at approximately $28,000. Finally, Stone House Investment Management LLC raised its stake in Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 50 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded down $3.52 during midday trading on Tuesday, hitting $370.62. The company had a trading volume of 1,212,524 shares, compared to its average volume of 1,644,877. The business’s 50 day simple moving average is $385.96 and its two-hundred day simple moving average is $348.19. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The stock has a market cap of $131.46 billion, a PE ratio of 66.90, a P/E/G ratio of 4.85 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period last year, the business earned $1.00 earnings per share. On average, sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analysts Set New Price Targets

ISRG has been the topic of a number of research analyst reports. Royal Bank of Canada raised their price target on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. Jefferies Financial Group boosted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. Barclays upped their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. BTIG Research raised their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Finally, Citigroup upped their target price on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus target price of $396.17.

Insider Activity at Intuitive Surgical

In other news, EVP Robert Desantis sold 1,498 shares of the firm’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the completion of the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $369.92, for a total transaction of $554,140.16. Following the sale, the executive vice president now owns 5,507 shares in the company, valued at $2,037,149.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Myriam Curet sold 5,318 shares of the firm’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $110,456.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 226,967 shares of company stock worth $87,848,586. 0.80% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.